Finding Your Footing: A Guide for the Newly Diagnosed
At a Glance
Renal cell carcinoma (RCC) is a type of kidney cancer that is often discovered incidentally during imaging scans for other issues. Newly diagnosed patients have a strong prognosis, as modern advancements like immunotherapy and targeted therapies have significantly improved survival rates.
Receiving a diagnosis of Renal Cell Carcinoma (RCC)—a type of kidney cancer that begins in the lining of very small tubes in the kidney—is often a profound shock. It is completely normal to feel overwhelmed, frightened, or even confused. Most people do not expect a cancer diagnosis to emerge from a routine check-up or a scan for a completely unrelated issue, but this is increasingly common for this specific disease [1][2].
While this moment feels like a crisis, it is important to know that you are entering a medical landscape that has transformed dramatically in recent years. This guide is designed to help you catch your breath and find your footing as you begin this journey.
Understanding the “Incidental” Diagnosis
If your tumor was found while you were being scanned for something else—like gallbladder issues, back pain, or an abdominal upset—you are not alone. Because the kidneys sit deep within the body, early-stage RCC rarely causes symptoms like pain or visible blood in the urine [1].
Today, most kidney tumors are found incidentally (by chance) due to the frequent use of advanced imaging like CT and MRI scans [1]. While it is jarring to find a problem you didn’t know you had, this “accidental” discovery is often a major advantage. It frequently allows doctors to catch the disease at an earlier, more treatable stage before it has had a chance to spread [3][4].
Three Stabilizing Facts
When the world feels like it is spinning, grounding yourself in data can help. Here are three facts about the current state of RCC care:
- Survival Rates Are Rising: The 5-year survival rate for kidney cancer has improved significantly over the last few decades, rising from roughly 34% in the mid-20th century to approximately 75% today [5][6].
- Early Detection is Powerful: When RCC is caught in a localized stage (meaning it is still only in the kidney), the prognosis is substantially better than in previous eras [7][6].
- Treatment has Revolutionized: Even for more advanced cases, the “toolbox” for doctors has expanded rapidly. The introduction of targeted therapies (drugs that attack specific molecules in cancer cells) and immune checkpoint inhibitors (treatments that help your immune system fight the cancer) has fundamentally changed how the disease is managed [8][9].
The Importance of Expert, Multidisciplinary Care
RCC is no longer a “one-size-fits-all” disease. It is now understood as a complex collection of different histologies (cell types) and molecular subtypes [10]. Because of this complexity, current guidelines emphasize the need for a multidisciplinary approach [11].
This means your care should ideally be managed by a team that includes:
- Urologic Surgeons: Experts in removing or treating the tumor while preserving as much kidney function as possible.
- Medical Oncologists: Specialists who manage systemic treatments like immunotherapy.
- Radiologists and Pathologists: Experts who specialize in reading kidney imaging and tissue samples.
Research suggests that surgical outcomes, such as having negative margins (no cancer cells left at the edge of the removed area), are often better when performed by highly experienced surgeons in high-volume medical centers [12][13].
Orienting Yourself
Right now, your only job is to move from a state of shock to a state of preparation. You do not need to make every decision today.
Cracking the Code: Understanding Your Pathology Report
Learn how to read your kidney cancer (RCC) pathology report. Understand WHO/ISUP grading, TNM staging, necrosis, sarcomatoid features, and margin status.
The Blueprint of the Tumor: Biology and Subtypes
Discover the different subtypes of Renal Cell Carcinoma (RCC), including clear cell and papillary. Learn how VHL mutations and genetic drivers impact treatment.
You are at the start of a process, not the end of the story. Modern medicine has more tools to fight this than ever before. You can read more about what to expect next in our sections on Standard Treatment for RCC and Survivorship and Life After RCC.
Common questions in this guide
Why was my kidney cancer found when I didn't have any symptoms?
What is the survival rate for renal cell carcinoma?
What types of doctors will treat my renal cell carcinoma?
Do I need to start treatment for my kidney tumor immediately?
Why is genetic testing important for renal cell carcinoma?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is the specific subtype of my renal cell carcinoma (e.g., clear cell, papillary), and how does that affect my treatment options?
- 2.What was the exact stage and grade of the tumor found on my scan?
- 3.How many RCC cases does this surgical or oncology team handle each year?
- 4.Is my case being reviewed by a multidisciplinary tumor board?
- 5.Are there any clinical trials available at this center for my specific stage and subtype?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (14)
- 1
Management of the Incidental Kidney Mass in the Nephrology Clinic.
Hu SL, Weiss RH
Clinical journal of the American Society of Nephrology : CJASN 2018; (13(9)):1407-1409 doi:10.2215/CJN.00860118.
PMID: 29653957 - 2
Temporal trends of the disease burden of renal cell carcinoma from 1992 to 2019 in the US: a population-based analysis.
Chen R, Tang T, Han J, et al.
Cancer causes & control : CCC 2025; (36(10)):1093-1105 doi:10.1007/s10552-025-02007-1.
PMID: 40358845 - 3
Outcomes of laparoscopic radical nephrectomy for elderly patients with localized renal cell carcinoma.
Lv J, Song R, Cai H, Lu C
Journal of B.U.ON. : official journal of the Balkan Union of Oncology 2019; (24(5)):2147-2154.
PMID: 31786888 - 4
Orbit and sinonasal metastasis as presenting sign of renal cell carcinoma.
Barajas-Ochoa Z, Suero-Abreu GA, Barajas-Ochoa A
BMJ case reports 2021; (14(4)) doi:10.1136/bcr-2020-240588.
PMID: 33849870 - 5
A case of renal cell carcinoma with tumor thrombus extension into the right atrium.
Whiting A, Shah N, Zucker J, et al.
Annals of medicine and surgery (2012) 2025; (87(6)):3819-3822 doi:10.1097/MS9.0000000000002837.
PMID: 40486613 - 6
Systemic Therapy for Metastatic Renal-Cell Carcinoma.
Choueiri TK, Motzer RJ
The New England journal of medicine 2017; (376(4)):354-366 doi:10.1056/NEJMra1601333.
PMID: 28121507 - 7
Renal cell carcinoma metastasis to the maxillary bone successfully treated with surgery after vascular embolization: a case report.
Nishii N, Shimamoto H, Ohsako T, et al.
Journal of medical case reports 2020; (14(1)):193 doi:10.1186/s13256-020-02522-6.
PMID: 33040735 - 8
Assessing improvements in metastatic renal cell carcinoma systemic treatments from the pre-cytokine to the immune checkpoint inhibitor eras: a retrospective analysis of real-world data.
Ishihara H, Takagi T, Kondo T, et al.
Japanese journal of clinical oncology 2021; (51(5)):793-801 doi:10.1093/jjco/hyaa232.
PMID: 33324983 - 9
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Choueiri TK, Powles T, Burotto M, et al.
The New England journal of medicine 2021; (384(9)):829-841 doi:10.1056/NEJMoa2026982.
PMID: 33657295 - 10
Perioperative systemic treatments in renal cell carcinoma.
Goswamy R, Kalemoglu E, Master V, Bilen MA
Frontiers in oncology 2024; (14()):1362172 doi:10.3389/fonc.2024.1362172.
PMID: 38841158 - 11
Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
Motzer RJ, Jonasch E, Agarwal N, et al.
Journal of the National Comprehensive Cancer Network : JNCCN 2017; (15(6)):804-834 doi:10.6004/jnccn.2017.0100.
PMID: 28596261 - 12
Impact of Positive Surgical Margins After Partial Nephrectomy.
Carvalho JAM, Nunes P, Tavares-da-Silva E, et al.
European urology open science 2020; (21()):41-46 doi:10.1016/j.euros.2020.08.006.
PMID: 34337467 - 13
Contemporary Outcomes of Robot-Assisted Partial Nephrectomy: Results from Two European Referral Institutions.
Barletta F, Frego N, de Angelis M, et al.
Cancers 2025; (17(13)) doi:10.3390/cancers17132104.
PMID: 40647403 - 14
Clinical Characteristics of Molecularly Defined Renal Cell Carcinomas.
Hu X, Tan C, Zhu G
Current issues in molecular biology 2023; (45(6)):4763-4777 doi:10.3390/cimb45060303.
PMID: 37367052
This guide provides educational information for patients newly diagnosed with renal cell carcinoma. It does not replace professional medical advice, diagnosis, or treatment from your multidisciplinary oncology team.
Get notified when new evidence is published on Renal cell carcinoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.